A detailed history of Winton Group LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Winton Group LTD holds 5,551 shares of BMY stock, worth $321,958. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,551
Holding current value
$321,958
% of portfolio
0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$39.66 - $51.75 $220,152 - $287,264
5,551 New
5,551 $287,000
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $324,872 - $368,342
6,771 New
6,771 $367,000
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $2.05 Million - $2.32 Million
-31,172 Reduced 78.0%
8,793 $609,000
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $1.6 Million - $1.89 Million
23,328 Added 140.22%
39,965 $2.88 Million
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $6,249 - $3.69 Million
-48,070 Reduced 74.29%
16,637 $1.18 Million
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $4.7 Million - $5.18 Million
64,707 New
64,707 $4.98 Million
Q1 2019

May 13, 2019

SELL
$45.12 - $53.8 $4.27 Million - $5.09 Million
-94,618 Closed
0 $0
Q4 2018

Feb 05, 2019

BUY
$48.76 - $63.23 $4.38 Million - $5.68 Million
89,906 Added 1908.02%
94,618 $4.92 Million
Q3 2018

Nov 02, 2018

SELL
$55.19 - $62.25 $15,398 - $17,367
-279 Reduced 5.59%
4,712 $0
Q2 2018

Aug 20, 2018

SELL
$50.53 - $62.98 $296,964 - $370,133
-5,877 Reduced 54.08%
4,991 $0
Q1 2018

May 21, 2018

BUY
$59.92 - $68.98 $25,166 - $28,971
420 Added 4.02%
10,868 $0
Q4 2017

Feb 13, 2018

SELL
$59.94 - $65.35 $462,976 - $504,763
-7,724 Reduced 42.5%
10,448 $640,000
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $766,592 - $884,711
13,880 Added 323.39%
18,172 $1.16 Million
Q2 2017

Aug 17, 2017

BUY
N/A
4,292
4,292 $239,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Winton Group LTD Portfolio

Follow Winton Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.